 Prediction of depth of invasion and lymph node metastasis in superficial pharyngeal cancer by magnifying endoscopy using the Japan Esophageal Society classification

Hayato Yamaguchi1 | Takashi Kawai2 | Masakatsu Fukuzawa1 | Daiki Nemoto1 | Yasuyuki Kagawa1 | Shin Kono1 | Sakiko Naito1 | Hiroki Sato3 | Naoyoshi Nagata2 | Mitsusige Sugimoto2 | Kiyohiko Tsukahara3 | Takao Itoi1

1Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan
2Department of Gastroenterological Endoscopy, Tokyo Medical University Hospital, Tokyo, Japan
3Department of Otorhinolaryngology, Head, and Neck Surgery, Tokyo Medical University, Tokyo, Japan

Correspondence
Hayato Yamaguchi, Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
Email: hayato10@tokyo-med.ac.jp

Abstract

Backgrounds: The pharynx has no muscularis mucosae, so it is unclear whether diagnostic techniques used for the esophagus can be applied to the pharynx. This study investigated the usefulness of magnifying endoscopy with narrowband imaging using the Japan Esophageal Society (JES) classification for predicting the depth of invasion and lymph node metastasis (LNM) in pharyngeal cancer.

Methods: A total of 123 superficial pharyngeal carcinoma lesions that had been observed preoperatively with magnifying endoscopy with narrowband imaging between January 2014 and June 2021 were analyzed. Predictors of subepithelial invasion (SEP) and LNM were sought based on endoscopic findings, including microvascular morphology, using the JES classification.

Results: The lesions were divided into carcinoma in situ (n = 41) and SEP (n = 82). Multivariate analysis identified B2–B3 vessels (odds ratio [OR] 6.54, 95% confidence interval [CI] 1.74–24.61, p = 0.005) and a middle/large avascular area (OR 4.15, 95% CI 1.18–14.62, p = 0.027) as independent predictors of SEP. Significant predictors of LNM were protruding type, B2–B3 vessels, middle/large avascular area, SEP venous invasion, lymphatic invasion, and tumor thickness > 1000 µm. Median tumor thickness increased significantly in the order of B1 < B2 < B3 vessels (B1, 305 µm; B2, 1045 µm; B3, 4043 µm; p < 0.001). The LNM rates for B1, B2, and B3 vessels were 1.6% (1/63), 4.8% (2/42), and 55.6% (10/18), respectively (p < 0.001).

Conclusions: Magnifying endoscopy with narrowband imaging using the JES classification could predict the depth of invasion in superficial pharyngeal carcinoma. The JES classification may contribute to the prediction of LNM, suggesting that it could serve as an alternative to tumor thickness.

Keywords
JES classification, magnifying endoscopy, narrowband imaging, pharyngeal cancer, tumor thickness
INTRODUCTION

The advent of gastrointestinal endoscopy has increased the opportunities for gastrointestinal endoscopists to detect and treat not only cancer of the gastrointestinal tract but also pharyngeal cancer.\(^1\)\(^-\)\(^5\) There is a close relationship between tumor depth, lymph node metastasis (LNM), and prognosis, so preoperative assessment of tumor depth is very important when determining the treatment strategy for gastrointestinal cancer. Magnifying endoscopy with narrowband imaging (ME-NBI) is useful for predicting the depth of gastrointestinal cancer because it can observe microvascular patterns.\(^6\)\(^,\)\(^7\) The Japan Esophageal Society (JES) classification system is now widely utilized to detect changes in the intrapapillary capillary loop pattern when diagnosing the depth of esophageal squamous cell carcinoma by magnifying endoscopy.\(^8\)\(^,\)\(^9\) However, despite recent advances in the diagnosis of gastrointestinal (including esophageal) cancers using magnifying endoscopy, there is still no method for the endoscopic diagnosis of depth of invasion in pharyngeal cancer. The pharynx has no muscularis mucosae, so it is unclear whether the diagnostic techniques used for the esophagus can be applied to the pharynx. The aim of this study was to investigate the usefulness of ME-NBI using the JES classification for predicting the depth of tumor invasion in pharyngeal cancer.

METHODS

Patients and lesions

A total of 139 lesions in 108 consecutive patients who underwent endoscopic submucosal dissection or endoscopic laryngopharyngeal surgery for pharyngeal tumors at Tokyo Medical University Hospital between January 2014 and June 2021 were identified. Twelve lesions in 12 patients who did not undergo ME-NBI, two lesions in two patients with low-grade intraepithelial neoplasia, one lesion in one patient with liposarcoma, and one lesion in one patient with lymphoepithelial carcinoma were excluded. Hence, a total of 123 lesions in 92 patients in whom an endoscopic diagnosis of pharyngeal cancer was made with ME-NBI using the JES classification were enrolled in the study. The pharyngeal cancers observed on ME-NBI were divided into a carcinoma in situ (CIS) group and a subepithelial invasion (SEP) group. White light imaging, ME-NBI, and pathological findings were analyzed retrospectively. Endoscopic findings were assessed by gastroenterologists who were blinded to the histopathological findings using endoscopic images stored in an endoscopic image filing system at the time of the surgery. Assessment with ME-NBI was performed immediately before performing resection in cases undergoing endoscopic laryngopharyngeal surgery or endoscopic submucosal dissection. The evaluators were gastroenterologists (Hayato Yamaguchi and Yasuyuki Kagawa) who had more than 5 years of experience performing ME-NBI and had examined more than 500 patients using ME-NBI.

The study was approved by the Ethics Committee of Tokyo Medical University Hospital (approval number T2021-0004) and conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from all patients whose data were included in the study.

Endoscopic procedures

Diagnostic ME-NBI (GIF-H260Z or GIF-H290Z; Olympus, Tokyo, Japan) was performed under general anesthesia in all patients. Endoscopic resection was indicated for stage Tis, T1, T2, and T3 pharyngeal cancers but not for those with muscle invasion or stage T4 disease. First, a curved rigid laryngoscope (Nagashima Medical Instruments Co., Ltd., Tokyo, Japan) was inserted in the pharyngeal lumen. Before resecting the lesion, the endoscopist observed the lesion in non-magnified white light imaging mode and magnified NBI mode using a magnifying endoscope. The extent and margins of the lesion were determined using the magnifying endoscope and iodine staining. A head and neck surgeon then inserted a curved electrosurgical needle knife (KD-600; Olympus) via the mouth and applied marks that would secure an adequate surgical margin of approximately 5 mm from the edge of the unstained area. The gastroenterologist injected a mixture of saline, indigo carmine, and epinephrine into the subepithelial layer beneath the lesion. Submucosal dissection or endoscopic laryngopharyngeal surgery was then performed while maintaining traction using an orally inserted curved grasping forceps. All lesions were removed by en bloc resection.

Prediction of tumor invasion using ME-NBI with the JES classification

The JES classification is a magnifying endoscopic diagnostic standard for superficial esophageal cancer devised by the JES.\(^10\) The microvessels of the lesion observed using magnifying endoscopy are categorized by degree of irregularity of weaving status, dilatation, caliber, and shape. Type B vessels are defined as abnormal microvessels with severe irregularity or highly dilated abnormal vessels and are classified as follows: B1, vessels with a loop-like formation (caliber,
FIGURE 1  Categorization of type B vessels by magnifying endoscopy with narrowband imaging using the Japan Esophageal Society classification. Type B vessels were defined as abnormal microvessels with severe irregularity or highly dilated abnormal vessels. (a) B1, a vessel with a loop-like formation (caliber approximately 20 µm). (b) B2, vessel without a loop-like formation (white arrowhead). (c) B3, a highly dilated vessel with a caliber (often > 60 µm) that appears to be more than three times that of a typical B2 vessel (white arrowhead).

approximately 20 µm); B2, vessels without loop-like formation; B3, highly dilated vessels with a caliber more than three times that of typical B2 vessels (caliber often > 60 µm; Figure 1). An avascular area (AVA) was defined as an area of low or no vascularity surrounded by type B microvessels. The AVA was classified as small (AVA-S, <0.5 mm in diameter), middle (AVA-M, ≥0.5 and ≤3 mm), or large (AVA-L, ≥3 mm; Figure 2).

Depth of pharyngeal cancer invasion was evaluated by ME-NBI using the JES classification. A lesion was assumed to be CIS if it contained only B1 vessels or AVA-S and to have reached the subepithelial layer or deeper if it contained B2/B3 vessels or AVA-M/L.

Evaluation of cervical LNM

Predictors of simultaneous cervical LNM were investigated based on endoscopic and pathological findings. Cervical LNM was evaluated by preoperative cervical ultrasonography, computed tomography (CT), magnetic resonance imaging, and positron emission tomography/CT (PET/CT). Patients with suspected LNM on these imaging modalities underwent fine-needle aspiration cytology to determine whether there was a malignant component. When cervical LNM was confirmed by fine-needle aspiration cytology, the patient underwent lymph node dissection. The neck was checked for LNM every 2–3 months by ultrasonography and CT and the
FIGURE 2  Categorization of the avascular area (AVA; defined as an area with low or no vascularity surrounded by type B microvessels) by magnifying endoscopy with narrowband imaging using the Japan Esophageal Society classification. (a) AVA-small (<0.5 mm in diameter). (b) AVA-middle (≥0.5 mm and ≤3 mm) (white dotted lines). (c) AVA-large (≥3 mm) (white dotted lines)

chest for LMN every 6 months by CT. Simultaneous LNM was defined as LNM observed by cervical ultrasonography, CT, magnetic resonance imaging, or PET/CT before or within 1 year after endoscopic diagnosis using a magnifying endoscope.

Histologic assessment

The resected specimens were fixed in 10% formalin, embedded in paraffin, cut into 2-mm-thick slices, and stained with hematoxylin-eosin. CIS was defined as a lesion in which tumor cells were localized in the epithelial layer and SEP as a lesion in which tumor cells invaded the subepithelial layer. Tumor thickness was measured as the distance from the surface to the deepest point of the tumor.

Statistical analysis

Results are presented as the median and interquartile range for continuous variables. Risk factors for tumor invasion of the subepithelial layer were analyzed using the Mann–Whitney U-test for quantitative variables and Fisher’s exact test or the chi-squared test for categorical variables. Variables with a p-value of <0.05 in univariate analysis were included in multiple logistic regression analysis. Tumor thickness was compared between the groups according to microvessel morphology using the
TABLE 1  Patient and lesion characteristics

| Characteristics                  | Value          |
|----------------------------------|----------------|
| Patients (n)                     | 92             |
| Age, years, median (IQR)         | 69 (63–73)     |
| Sex (male/female)                | 86/6           |
| Body-mass-index, median (IQR)    | 22.0 (19.5–23.6) |
| Alcohol intake (no or mild/moderate/heavy) | 27/29/36 |
| Smoking (no or mild/heavy)       | 28/64          |
| Lesions (n)                      | 123            |
| Tumor size, mm, median (IQR)     | 19 (13–25)     |
| Tumor location, n (%)            |                |
| Hypopharynx                      | 93 (75.6)      |
| Pyriform sinus                   | 53 (43.1)      |
| Postcricoid                      | 15 (12.2)      |
| Posterior wall                   | 25 (20.3)      |
| Oropharynx                       | 23 (18.7)      |
| Anterior wall                    | 8 (6.5)        |
| Posterior wall                   | 9 (7.3)        |
| Lateral wall                     | 6 (4.9)        |
| Larynx                           | 7 (5.7)        |
| Supraglottic                     | 7 (5.7)        |

| Tumor morphology (0-I/0-IIa/0-IIb/0-IIc) | 26/47/38/12 |
| Type B vessels (B1/B2/B3)              | 63/42/18    |
| AVA (small/middle/large)              | 62/40/21    |
| T classification (Tis/T1/T2/T3)        | 41/37/38/7  |
| Depth of tumor invasion (CIS/SEP)      | 41/82       |
| Tumor thickness, µm, median (IQR)     | 486 (284–1600) |
| Venous invasion                      | 12 (9.8)    |
| Lymphatic invasion                   | 13 (10.6)   |

Abbreviations: AVA, avascular area; CIS, carcinoma in situ; IQR, interquartile range; SEP, subepithelial invasion.
aAlcohol: no or mild, < 10 g/day; moderate, ≥20 g and < 30 g/day; heavy, ≥30 g/day.
bSmoking: no or mild, Brinkman index < 400; heavy, Brinkman index ≥400.

Kruskal–Wallis test. All statistical analyses were performed using the SPSS software program (version 28; IBM Corp., Armonk, NY, USA). A p-value < 0.05 was considered statistically significant.

RESULTS

Patient and lesion characteristics

Patient and lesion characteristics are shown in Table 1. The median age was 69 (63–73) years. The median tumor size was 19 (13–25) mm, and the macroscopic type was 0-I in 26 lesions, 0-IIa in 47 lesions, 0-IIb in 38 lesions, and 0-IIc in 12 lesions. Of the 123 lesions, 41 were pathologically diagnosed as Tis, 37 as T1, 38 as T2, and seven as T3. Microvascular morphology on ME-NBI was classified as follows: B1/B2/B3 63/42/18 and AVA-S/AVA-M/AVA-L 62/40/21. In terms of depth of invasion, 41 lesions were diagnosed as CIS and 82 as SEP.

Predictors of SEP

Predictors of SEP are shown in Table 2. All lesions were categorized as CIS or SEP. In univariate analysis, protruding-type lesions (p < 0.001), B2–B3 vessels (p < 0.001), and AVA-M/L (p < 0.001) were significantly more common in the SEP group than in the CIS group. There was no significant difference in age, sex, body mass index, tumor location or size, redness, white coat, or erosion between the CIS group and SEP group. Multivariate analysis identified B2–B3 vessels (odds ratio [OR] 6.54, 95% confidence interval [CI] 1.74–24.61, p = 0.005) and AVA-M/L (OR 4.15, 95% CI 1.18–14.62, p = 0.027) to be independent predictors of SEP.

Diagnostic value of ME-NBI

The diagnostic value of ME-NBI for estimating SEP and tumor thickness is shown in Table 3. In the SEP group, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy of type B2–B3 vessels for diagnosing tumor invasion were 68.3%, 90.2%, 93.3%, 58.7%, and 75.6%, respectively; the respective values for AVA-M/L were 68.3%, 87.8%, 91.8%, 58.1%, and 74.8%. The sensitivity, specificity, PPV, NPV, and diagnostic accuracy of type B2–B3 vessels for detection of tumor thickness ≥1000 µm were 93.2%, 75.9%, 68.3%, 95.2%, and 82.1%, respectively; the respective values for AVA-M/L were 81.8%, 68.4%, 59.0%, 87.1%, and 73.2%.

Predictors of cervical LNM

Predictors of cervical LNM are shown in Table 4. Of the 123 lesions, 13 (10.6%) were positive for LNM and 110 (89.4%) were negative. In univariate analysis, significant predictors of LNM were protruding-type morphology (p < 0.001), B2–B3 vessels (p < 0.001), AVA-M/L (p = 0.001), SEP (p = 0.004), venous invasion (p = 0.007), lymphatic invasion (p < 0.001), and tumor thickness > 1000 µm (p < 0.001).

Relationship between ME-BI findings and depth of invasion

The relationship between ME-NBI findings and depth of invasion is shown in Table 5. B1 vessels were detected in 63 lesions, B2 vessels in 42, and B3 vessels in 18.
## Table 2: Univariate and multivariate analyses of potential predictors of subepithelial invasion in patients with pharyngeal cancer

| Predictive factor | CIS (n = 41) | SEP (n = 82) | Univariate analysis | Multivariate analysis |
|-------------------|--------------|--------------|---------------------|----------------------|
|                   |              |              | OR (95% CI)         | p-value              |
| **Factors associated with patient’s characteristics** |              |              |                     |                      |
| Age, years, n (%) |              |              |                     |                      |
| < 65              | 17 (41.5)    | 28 (34.1)    | 1.00 (reference)    |                      |
| ≥ 65              | 24 (58.5)    | 54 (65.9)    | 1.37 (0.63–2.95)    | 0.427                |
| Sex, n (%)        |              |              |                     |                      |
| Male              | 39 (95.1)    | 78 (95.1)    | 1.00 (reference)    |                      |
| Female            | 2 (4.9)      | 4 (4.9)      | 1.00 (0.18–5.70)    | 0.654                |
| Body mass index, n (%) |           |              |                     |                      |
| < 25              | 37 (90.2)    | 74 (90.2)    | 1.00 (reference)    |                      |
| ≥ 25              | 4 (9.8)      | 8 (9.8)      | 1.00 (0.28–3.54)    | 0.615                |
| **Factors associated with non-magnified WLI findings** |              |              |                     |                      |
| Tumor location, n (%) |           |              |                     |                      |
| Hypopharynx or oropharynx | 37 (90.2) | 79 (96.3) | 1.00 (reference) |                      |
| Larynx            | 4 (9.8)      | 3 (3.7)      | 0.35 (0.08–1.65)    | 0.167                |
| Tumor size, mm, n (%) |           |              |                     |                      |
| < 40 mm           | 40 (97.6)    | 75 (91.5)    | 1.00 (reference)    |                      |
| ≥ 40 mm           | 1 (2.4)      | 7 (8.5)      | 3.73 (0.44–31.42)   | 0.186                |
| Tumor morphology, n (%) |           |              |                     |                      |
| Flat type (0-IIa/0-II/0-IIc) | 40 (97.6) | 57 (69.5) | 1.00 (reference) | 1.00 (reference) |
| Protruded type (0-I) | 1 (2.4)    | 25 (30.5)    | 17.54 (2.28–134.82) | <0.001 |
| Redness, n (%)    |              |              |                     |                      |
| Negative          | 29 (70.7)    | 47 (57.3)    | 1.00 (reference)    |                      |
| Positive          | 12 (29.3)    | 35 (42.7)    | 1.80 (0.81–4.02)    | 0.149                |
| White coat, n (%) |              |              |                     |                      |
| Negative          | 34 (82.9)    | 57 (69.5)    | 1.00 (reference)    |                      |
| Positive          | 7 (17.1)     | 25 (30.5)    | 2.13 (0.83–5.45)    | 0.11                 |
| Erosion, n (%)    |              |              |                     |                      |
| Negative          | 31 (75.6)    | 51 (62.2)    | 1.00 (reference)    |                      |
| Positive          | 10 (24.4)    | 31 (37.8)    | 1.88 (0.81–4.37)    | 0.137                |
| **Factors associated with magnified NBI findings** |              |              |                     |                      |
| Type B vessels, n (%) |           |              |                     |                      |
| B 1               | 37 (90.2)    | 26 (31.7)    | 1.00 (reference)    | 1.00 (reference)     |
| B 2 + B 3         | 4 (9.8)      | 56 (68.3)    | 19.92 (6.43–61.78)  | <0.001  |
| AVA, n (%)        |              |              |                     |                      |
| AVA-S             | 36 (87.8)    | 26 (31.7)    | 1.00 (reference)    | 1.00 (reference)     |
| AVA-M + L         | 5 (12.2)     | 56 (68.3)    | 15.51 (5.46–44.08)  | <0.001  |

Abbreviations: AVA, avascular area; CI, confidence interval; CIS, carcinoma in situ; NBI, narrowband imaging; OR, odds ratio; SEP, subepithelial invasion; WLI, white light imaging.

In the SEP group, B1, B2, and B3 vessels were found in 41.3% (26 lesions), 90.5% (38 lesions), and 100% (18 lesions), respectively. The median tumor thickness of lesions with B1, B2, and B3 vessels was 305, 1045, and 4042.5 μm, respectively. The respective LNM rates for B1, B2, and B3 vessels were 1.6% (one lesion), 4.8% (two lesions), and 55.6% (10 lesions). Significant correlations were observed between type B vessels and tumor depth, tumor thickness, and LNM (p < 0.001). AVA-S, AVA-M, and AVA-L were involved in 63, 40, and
### TABLE 3  Diagnostic value of magnifying endoscopy with narrowband imaging for estimating subepithelial invasion and tumor thickness

| Diagnosis for SEP invasion | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | Accuracy (95% CI) |
|----------------------------|----------------------|----------------------|--------------|--------------|------------------|
| Type B2 + B3               | 68.3 (57.1–78.1)     | 90.2 (76.9–97.3)     | 92.3 (83.8–98.2) | 58.7 (45.6–71.0) | 75.6 (67.0–82.9) |
| AVA-M + L                  | 68.3 (57.1–78.1)     | 87.8 (73.8–95.9)     | 91.8 (81.9–97.3) | 58.1 (44.8–70.5) | 74.8 (66.2–82.2) |

### Diagnosis for tumor thickness ≥1000 µm

| Diagnosis for tumor thickness ≥1000 µm | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | Accuracy (95% CI) |
|---------------------------------------|----------------------|----------------------|--------------|--------------|------------------|
| Type B2 + B3                          | 93.2 (81.3–96.8)     | 75.9 (65.0–84.9)     | 68.3 (55.0–79.7) | 95.2 (86.7–99.0) | 82.1 (74.2–88.4) |
| AVA-M + L                             | 81.8 (67.3–91.8)     | 68.4 (56.9–78.4)     | 59.0 (45.7–71.4) | 87.1 (76.1–94.3) | 73.2 (64.4–80.8) |

Abbreviations: AVA, avascular area; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; SEP, subepithelial invasion.

### TABLE 4  Univariate analysis of potential predictors of cervical lymph node metastasis in pharyngeal cancer

| Predictive factor                      | LNM (−) (n = 110) | LNM (+) (n = 13) | OR (95% CI) | p-value |
|----------------------------------------|-------------------|------------------|-------------|---------|
| Factors associated with patient’s characteristics |
| Age, years, n (%)<65                   | 41 (37.3)         | 4 (30.8)         |             | 0.447   |
|                                       | 69 (62.7)         | 9 (69.2)         | 1.34 (0.39–4.61) |         |
| Sex, n (%)                            |                   |                  |             |         |
| Male                                   | 104 (94.5)        | 13 (100.0)       |             | 0.504   |
| Female                                 | 6 (5.5)           | 0 (0.0)          | (incalculable) |         |
| Body mass index, n (%)<25              | 101 (91.8)        | 10 (76.9)        |             | 0.116   |
|                                       | 9 (8.2)           | 3 (23.1)         | 3.37 (0.78–14.49) |         |
| Factors associated with non-magnified WLI findings |
| Tumor location, n (%)                  |                   |                  |             |         |
| Hypopharynx or oropharynx              | 103 (93.6)        | 13 (100.0)       |             | 0.448   |
| Larynx                                 | 7 (6.4)           | 0 (0.0)          | (incalculable) |         |
| Tumor size, mm, n (%)<40 mm            | 104 (94.5)        | 11 (84.6)        |             | 0.200   |
|                                       | 6 (5.5)           | 2 (15.4)         | 3.15 (0.57–17.54) |         |
| Tumor morphology, n (%)                |                   |                  |             | <0.001  |
| Flat type (0-IIa/0-IIb/0-IIc)          | 92 (83.6)         | 5 (38.5)         |             |         |
| Protruded type (0-I)                   | 18 (16.4)         | 8 (61.5)         | 8.18 (2.40–27.87) |         |
| Redness, n (%)                         |                   |                  |             |         |
| Negative                               | 67 (60.9)         | 9 (69.2)         |             | 0.396   |
| Positive                               | 43 (39.1)         | 4 (30.8)         | 0.69 (0.20–2.39) |         |
| White coat, n (%)                      |                   |                  |             |         |
| Negative                               | 83 (75.5)         | 8 (61.5)         |             | 0.222   |
| Positive                               | 27 (24.5)         | 5 (38.5)         | 1.92 (0.58–6.37) |         |
| Erosion, n (%)                         |                   |                  |             |         |
| Negative                               | 75 (68.2)         | 7 (53.8)         |             | 0.230   |
| Positive                               | 35 (31.8)         | 6 (46.2)         | 1.84 (0.58–5.87) |         |
| Factors associated with magnified NBI findings |
| Type B vessels, n (%)                  |                   |                  |             |         |
| B 1                                     | 62 (56.4)         | 1 (7.7)          |             | <0.001  |
| B 2 + B 3                               | 48 (43.6)         | 12 (92.3)        | 15.50 (1.95–123.39) |         |
| AVA, n (%)                              |                   |                  |             |         |
| AVA-S                                   | 61 (55.5)         | 1 (7.7)          |             |         |
| AVA-M + L                               | 49 (44.5)         | 12 (92.3)        | 14.94 (1.88–118.90) | 0.001   |

(Continues)
TABLE 4  (Continued)

| Predictive factor | LNM (−) (n = 110) | LNM (+) (n = 13) | OR (95% CI) | p-value |
|-------------------|--------------------|------------------|-------------|---------|
| **Pathological findings** | | | | |
| Depth of tumor invasion, n (%) | | | | |
| CIS | 41 (37.3) | 0 (0.0) | | |
| SEP | 69 (62.7) | 13 (100.0) | (incalculable) | 0.004 |
| Venous invasion, n (%) | | | | |
| negative | 102 (92.7) | 9 (69.2) | | |
| positive | 8 (7.3) | 4 (30.8) | 5.67 (1.43–22.53) | 0.007 |
| Lymphatic invasion, n (%) | | | | |
| negative | 103 (93.6) | 7 (53.8) | | |
| positive | 7 (6.4) | 6 (46.2) | 12.61 (3.32–47.80) | <0.001 |
| Tumor thickness, n (%) | | | | |
| <1000 µm | 79 (71.8) | 0 (0.0) | | |
| ≥1000 µm | 31 (28.2) | 13 (100.0) | (incalculable) | <0.001 |

Abbreviations: AVA, avascular area; CI, confidence interval; CIS, carcinoma in situ; LNM, lymph node metastasis; NBI, narrowband imaging; OR, odds ratio; SEP, subepithelial invasion; WLI, white light imaging.

TABLE 5  Relationship between findings on magnified endoscopy with narrowband imaging and depth of invasion

| Type B vessels | B1 (n = 63) | B2 (n = 42) | B3 (B = 18) | p-value |
|----------------|-------------|-------------|-------------|---------|
| SEP n (%) | 26/63 (41.3) | 38/42 (90.5) | 18/18 (100.0) | <0.001 (B1 vs. B2, B1 vs. B3) |
| Tumor thickness, μm, median (IQR) | 305 (211.5–419.5) | 1045 (446.3–1854.8) | 4042.5 (2250–7243.8) | <0.001 (B1 vs. B2 vs. B3) |
| LNM, n (%) | 1/63 (1.6) | 2/42 (4.8) | 10/18 (55.6) | <0.001 (B1 vs. B3, B2 vs. B3) |
| AVA | AVA-S (n = 62) | AVA-M (n = 40) | AVA-L (n = 21) | p-value |
| SEP n (%) | 26/62 (41.9) | 35/40 (87.5) | 21/21 (100.0) | <0.001 (AVA-S vs. AVA-M, AVA-S vs. AVA-L) |
| Tumor thickness, μm, median (IQR) | 331 (210.3–537.5) | 885.5 (378.5–1443.8) | 3500 (2000–7342) | <0.001 (AVA-S vs. AVA-M vs. AVA-L) |
| LNM, n (%) | 1/62 (1.6) | 6/40 (15.0) | 6/21 (28.6) | <0.001 (AVA-S vs. AVA-M, AVA-S vs. AVA-L) |

Abbreviations: AVA, avascular area; IQR, interquartile range; LNM, lymph node metastasis; NBI, narrowband imaging; SEP, subepithelial invasion.

21 lesions, respectively. In the SEP group, the AVA-S, AVA-M, and AVA-L rates were 41.9% (26 lesions), 87.5% (35 lesions), and 100% (21 lesions), respectively; the respective median tumor thickness values were 331, 885.5, and 3500 µm and the respective LNM rates were 1.6% (one lesion), 15.0% (six lesions), and 28.6% (six lesions). A significant correlation was found between AVA and tumor depth, tumor thickness, and LNM (p < 0.001).

**DISCUSSION**

In this study, B2–B3 vessels and AVA-M/L were identified as predictors of SEP in patients with pharyngeal cancer. Therefore, the use of ME-NBI with the JES classification could predict the depth of superficial pharyngeal carcinoma. Moreover, there were significantly more B2–B3 vessels and findings of AVA-M/L in the LNM-positive group than in the LNM-negative group, suggesting that the JES classification may be useful for predicting LNM.

It has also been reported that esophageal squamous cell carcinoma and pharyngeal squamous cell carcinoma are pathologically similar.11,12 In terms of esophageal cancer, the JES classification shows that B1 vessels and an AVA-S correspond to the invasion of the epithelium/lamina propria mucosa, B2 vessels, and AVA-M to the invasion of the muscularis mucosae/upper third, and B3 vessels and AVA-L to the invasion of the middle third.8,10 In this study, the specificity and PPV of type B2–B3 vessels for SEP were 90.2% and 93.3%, respectively, and the specificity and PPV of AVA-M/L for SEP were 87.8% and 91.8%. Therefore, there is a possibility of SEP in pharyngeal carcinoma with these findings. In particular, SEP was found in 18 of our cases with B3 vessels and 21 with AVA-L, so these two features are important for a definitive diagnosis of SEP. Predicting the depth of laryngeal cancer prevents a positive vertical
### Table 6: Summary of previous reports on magnifying endoscopy with narrowband imaging for pharyngeal cancer

| First author | Year | Period       | Study design | n    | Tumor invasion | Type B vessels | Tumor thickness | Factors associated with SEP | Frequency of LNM/LVI |
|--------------|------|--------------|--------------|------|----------------|----------------|-------------------|-----------------------------|---------------------|
| Fujii        | 2010 | 2002–2006    | Prospective  | 104  | CIS: 75 (72.1%) | SEP: 29 (27.9%) | N/A               | CIS: 125–1000 µm SEP: 300–3500 µm (range) | N/A                 |
|              |      |              |              |      |                |                |                   | Microvascular density tumor thickness, tumor size | LNM(+): 1/104 (1.0%) ly(+): 1/104 (1.0%) v(+): 6/104 (5.8%) |
| Tateya       | 2015 | 2007–2014    | Retrospective| 139  | CIS: 101 (72.7%)| SEP: 37 (26.6%)| MP: 1 (0.7%)     | Type 0-I            | ly(+): 3/139 (2.2%) v(+): 1/139 (0.7%) |
| Kikuchi      | 2015 | 2008–2012    | Retrospective| 146  | CIS: 41 (28.1%) | SEP: 105 (71.9%)| B1: 128 (87.7%)  | B1: 650.3 ± 577.4 µm B2: 720.9 ± 418.1 µm B3: 2256.5 ± 625.4 µm | Non B1 vessels      |
| Eguchi       | 2019 | 2016–2018    | Retrospective| 59   | CIS: 21 (35.6%) | CIS-SEP: 13 (22.0%) | B1: 26 (44.1%) | B1: 563 ± 614 µm B2: 1364 ± 1320 µm B3: 2825 ± 29,999 µm | Non B1 vessels      |
| Katada       | 2020 | 2006–2016    | retrospective| 92   | CIS: 34 (37.0%) | SEP: 58 (63.0%) | B1: 32 (47.8%)  | B1: 580 ± 530 µm B2: 1264 ± 1238 µm B3: 4583 ± 3079 µm | White coat, main macroscopic type, macroscopic appearance, type B vessels |
| Sunakawa, H  | 2021 | 2011–2017    | retrospective| 219  | CIS: 145 (66.2%)| SEP: 74 (33.8%) | B1: 181 (82.6%) | B1: 275 µm B2/3: 1325 µm (median) | B2/3 vessels        |

Abbreviations: CIS, carcinoma in situ; LNM, lymph node metastasis; LVI, lymphovascular invasion; ly, lymphatic invasion; N/A, not applicable; NBI, narrowband imaging; SEP, subepithelial invasion; v, venous invasion.
margin when resecting the tumor. Also, endoscopic submucosal dissection and endoscopic laryngopharyngeal surgery are basically not indicated for pharyngeal cancer that invades the deep muscle layer of bone. For these reasons, predicting the depth of laryngeal cancer has several benefits for minimally invasive treatments. The frequency of LNM based on the depth of invasion has been clarified in esophageal cancer. Cancers involving the epithelium/lamina propria mucosa have almost no risk of LNM, whereas the rate of LNM for cancers in the muscularis mucosae/upper third is reported to be about 10% and 20%–40% for cancers in the middle and lower thirds.10,13,14 Unlike esophageal cancer, the prevailing view is that the depth of pharyngeal cancer can be measured by substituting tumor thickness because the pharynx has no muscularis mucosae. The frequency of LNM of pharyngeal carcinoma reportedly increases when the tumor thickness is >1000 µm.15–17 In this study, 13 cases of pharyngeal carcinoma were found to have LNM, and all had a tumor thickness >1000 µm. However, tumor thickness and lymphovascular invasion related to LNM are only pathological findings, and resected specimens are necessary to obtain this information. Our LNM group had significantly more B2–B3 vessels and AVA-M/L than our non-LNM group, suggesting that in addition to tumor thickness, B vessels and AVA may be indicators of LNM. In particular, we found that the sensitivity and NPV of type B2 + B3 vessels for LNM were 93.2% and 95.2%, respectively. Therefore, the risk of LNM would be expected to be low if these findings were negative. There has been a report suggesting that submucosal invasion is more common when esophageal cancer has a protruding-type morphology.18 In the present study, SEP was found in 25 (96.2%) of 26 pharyngeal carcinomas, which were significantly more likely to be the protruding type than the flat type. A combination of the JES classification and tumor morphology may improve the diagnostic accuracy of the depth of invasion in patients with pharyngeal carcinoma.

The findings of previous reports on ME-NBI for pharyngeal cancer are summarized in Table 6.17,19–23 Pharyngeal carcinoma with B2–B3 vessels has been reported to be significantly more likely to show SEP17,21 Furthermore, there are a few reports on the correlation between B vessels and tumor thickness.22,23 In this study, the tumor thickness was significantly greater in the order of B1, B2, and B3 vessels, suggesting that the thickness of the tumor, which may be a risk factor for LNM, can be predicted by observing the microvascular pattern. In gastrointestinal cancers, if the depth of the tumor is shallower than the mucosal layer, there is almost no chance of LNM.24–26 Moreover, a previous study found that LNM is very rare in cases of pharyngeal cancer with a pathological diagnosis of CIS.1,17 As in previous reports, we found almost no LNM in pharyngeal carcinoma diagnosed as CIS, which suggests a correlation between tumor depth and LNM. However, there are many cases of LNM in pharyngeal carcinoma that have invaded the subepithelial layer, so preoperative assessment of tumor depth is important when determining the treatment strategy. Katada et al. previously reported an association between JES classification and lymphatic invasion but did not separately analyze lymphatic invasion and LNM, treating them as the same factor.22 This study is one of the few to suggest a correlation between JES classification and LNM. Currently, fiberscopes for the head and neck are not yet equipped with a magnifying observation function and there are few reports of ME-NBI of laryngeal cancer, so it is worth considering its usefulness.

This study has several limitations. First, it had a retrospective design and was performed at a single institution. In this study, only 13 cases of pharyngeal carcinoma were found to have LNM, and this small sample size may have introduced a degree of bias. Only univariate analysis was performed to identify features that can predict LNM in pharyngeal cancer because of the small number of cases for comparison. Second, in this study, suspected LNM on preoperative imaging such as cervical ultrasonography, CT, and magnetic resonance imaging was confirmed by pathology, but pathology was not obtained for cases in which LNM was not suspected on these modalities. Preoperative imaging is not perfect for detecting LNM, and not pathologically confirming the status of LNM in all cases may have affected the results. Third, LNM was associated with histological findings including tumor thickness. Obtaining information about the risk of LNM by preoperative ME-NBI may be useful for providing explanations to patients and deciding the treatment strategy before surgery, but the risk of LNM can be predicted based on histological findings, so ME-NBI findings may not always be necessary. Fourth, the observation period was short, with LNM defined as occurring within 1 year of endoscopic diagnosis using a magnifying endoscope. The long-term prognosis of LNM in pharyngeal carcinoma is important, but some patients in this study could not be followed for more than 1 year after treatment. Therefore, prospective multicenter studies are needed to investigate the long-term course of metachronous LNM in the future.

CONCLUSIONS

ME-NBI using the JES classification could predict the depth of invasion in superficial pharyngeal carcinoma. The JES classification may contribute to the prediction of LNM, suggesting that it could serve as an alternative to tumor thickness.

ACKNOWLEDGMENTS

The authors are indebted to the native English-speaking editors of ThinkSCIENCE Inc., Tokyo, Japan, for editorial review of the English manuscript.
CONFLICT OF INTEREST
The authors declare no conflict of interest.

FUNDING INFORMATION
None.

ORCID
Hayato Yamaguchi https://orcid.org/0000-0002-7533-1061
Sakiko Naito https://orcid.org/0000-0002-9433-8437
Takao Itoi https://orcid.org/0000-0002-5208-554X

REFERENCES
1. Muto M, Satake H, Yano T et al. Long-term outcome of transoral organ-preserving pharyngeal endoscopic resection for superficial pharyngeal carcinoma. Gastrointest Endosc 2011; 74: 477–84.
2. Iizuka T, Kikuchi D, Hoteya S, Yahagi N, Takeda H. Endoscopic submucosal dissection for treatment of mesopharyngeal and hypopharyngeal carcinomas. Endoscopy 2009; 41: 113–7.
3. Yamaguchi H, Sato H, Tsukahara K et al. Co-treatment with endoscopic laryngopharyngeal surgery and endoscopic submucosal dissection. Auris Nasus Larynx 2021; 48: 457–63.
4. Okada K, Tsuchida T, Ishiyama A et al. Endoscopic mucosal resection and endoscopic submucosal dissection for en bloc resection of superficial pharyngeal carcinomas. Endoscopy 2012; 44: 556–64.
5. Yamaguchi H, Fukuzawa M, Kawai T et al. Predictive factors of postendoscopic submucosal dissection electrocoagulation syndrome and the utility of computed tomography scan after esophageal endoscopic submucosal dissection. Digestion 2020; 101: 579–89.
6. Inoue H, Honda T, Nagai K et al. Ultra-high magnification endoscopic observation of carcinoma in situ of the esophagus. Dig Endosc 1997; 9: 16–8.
7. Katada C, Muto M, Tanabe S et al. Surveillance after endoscopic mucosal resection or endoscopic submucosal dissection for esophageal squamous cell carcinoma. Dig Endosc 2013; 25: 39–43.
8. Sato H, Inoue H, Ikeda H et al. Utility of intrapapillary capillary loops seen on magnifying narrow-band imaging in estimating invasive depth of esophageal squamous cell carcinoma. Endoscopy 2015; 47: 122–8.
9. Arima M, Tada M, Arima H. Evaluation of microvascular patterns of superficial esophageal cancers by magnifying endoscopy. Esophagus 2005; 2: 191–7.
10. Oyama T, Inoue H, Arima M et al. Prediction of the invasion depth of superficial squamous cell carcinoma based on microvessel morphology: Magnifying endoscopic classification of the Japan Esophageal Society. Esophagus 2017; 14: 105–12.
11. Goda K, Dobashi A, Tajiri H. Perspectives on narrow-band imaging endoscopy for superficial squamous neoplasms of the oropharynx and esophagus. Dig Endosc 2014; 26: 1–11.
12. Hanaoka N, Ishihara R, Takeuchi Y et al. Endoscopic submucosal dissection as minimally invasive treatment for superficial pharyngeal cancer: A phase II study (with video). Gastrointest Endosc 2015; 82: 1002–8.
13. Kimura H, Yoshida M, Tanaka M et al. Preoperative indicators of misdiagnosis in invasion depth staging of esophageal cancer: Pitfalls of magnifying endoscopy with narrow-band imaging. Dig Endosc 2020; 32: 56–64.
14. Goda K, Tajiri H, Ikegami M et al. Magnifying endoscopy with narrow band imaging for predicting the invasion depth of superficial esophageal squamous cell carcinoma. Dis Esophagus 2009; 22: 453–60.
15. Yoshio T, Tsuchida T, Ishiyama A et al. Efficacy of double-scope endoscopic submucosal dissection and long-term outcomes of endoscopic resection for superficial pharyngeal cancer. Dig Endosc 2017; 29: 152–9.
16. Imai K, Tanaka M, Hasuiko N et al. Feasibility of a “resect and watch” strategy with endoscopic resection for superficial pharyngeal cancer. Gastrointest Endosc 2013; 78: 22–9.
17. Kikuchi D, Iizuka T, Yamada A et al. Utility of magnifying endoscopy with narrow band imaging in determining the invasion depth of superficial pharyngeal cancer. Head Neck 2015; 37: 846–50.
18. Endo M, Kawano T. Detection and classification of early squamous cell esophageal cancer. Dis Esophagus 1997; 10: 155–8.
19. Fuji S, Yamazaki M, Muto M, Ochiai A. Microvascular irregularities are associated with composition of squamous epithelial lesions and correlate with subepithelial invasion of superficial-type pharyngeal squamous cell carcinoma. Histopathology 2010; 56: 510–22.
20. Tateya I, Morita S, Muto M et al. Magnifying endoscopy with NBI to predict the depth of invasion in laryngo-pharyngeal cancer. Laryngoscope 2015; 125: 1124–9.
21. Eguchi K, Matsui T, Mukai M, Sugimoto T. Prediction of the depth of invasion in superficial pharyngeal cancer: Microvessel morphological evaluation with narrowband imaging. Head Neck 2019; 41: 3970–5.
22. Katada C, Okamoto T, Ichinoe M et al. Prediction of lymph-node metastasis and lymphatic invasion of superficial pharyngeal cancer on narrow band imaging with magnifying endoscopy. Auris Nasus Larynx 2020; 47: 128–34.
23. Sunakawa H, Hori K, Kadota T et al. Relationship between the microvascular patterns observed by magnifying endoscopy with narrow-band imaging and the depth of invasion in superficial pharyngeal squamous cell carcinoma. Esophagus 2021; 18: 111–7.
24. Saito Y, Uraoka T, Yamaguchi Y et al. A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video). Gastrointest Endosc 2010; 72: 1217–25.
25. Ishikawa S, Togashi A, Inoue M et al. Indications for EMR/ESD in cases of early gastric cancer: Relationship between histological type, depth of wall invasion, and lymph node metastasis. Gastric Cancer 2007; 10: 35–8.
26. Repici A, Hassan C, Carlino A et al. Endoscopic submucosal dissection in patients with early esophageal squamous cell carcinoma: Results from a prospective Western series. Gastrointest Endosc 2010; 71: 715–21.